Lead Product(s) : Ramatroban
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
Details : Ramatroban (KARE 101), a dual blocker of thromboxane and prostanoid receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, and evidence for rapid relief of dyspnea and hypoxemia in COVID...
Brand Name : KARE 101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 05, 2022
Lead Product(s) : Ramatroban
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?